On the path to finding different ways to treat cancer, various research and trials have been carried out. This is done in order to find safe and effective treatments other than the standard ones. Every drug that is in use now was once tested in clinical trials. The clinical studies mainly focus on finding a safe, effective, and better treatment or diagnostic procedure. They evaluate new chemotherapy or radiotherapy drugs for better treatment of cancer.
Taking part in clinical trials can benefit people by receiving treatment before it is available. As the coin has two sides, there are some risks with the clinical trials, including its side effects and the possibility of new clinical trials not working. People also conduct clinical trials on drugs and other therapies that can relieve the symptoms and side effects of treatments like chemotherapy, radiotherapy, etc.
Participating in clinical trials can have many reasons. For some people, taking part in a clinical trial is the only option to receive the best treatment for the type of cancer. Because standard treatments are not perfect, people are willing to face the uncertainty and challenges of a clinical trial to seek a better result.
Some clinical trials study new ways to relieve symptoms and side effects during treatment. Others learn ways to manage the late effects that may happen a long time after treatment.
Financial and Eligibility criteria
Insurance and the costs of clinical trials change depending upon location and by study. People reimburse some of the expenses from participating in the clinical trial in several programs.
Clinical trials also have specific “eligibility criteria” rules that help research patients be safe. You and your research team carefully review these criteria together. People participating in a clinical trial can stop participating at any time for any medical or personal reasons. The reasons may include that the new treatment is not working or has severe side effects. Experts keep an eye on clinical trials for any problems with each study.